Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation.
Dosimetry
Prostate cancer
Radionuclide therapy
[177Lu]Lu-PSMA
mHSPC
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
24 Jan 2023
24 Jan 2023
Historique:
received:
25
07
2022
accepted:
11
01
2023
entrez:
24
1
2023
pubmed:
25
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Dosimetry in [ Ten patients with metastatic hormone-sensitive prostate cancer received two cycles of [ Accurate lesion dosimetry is possible using one-time point SPECT imaging at 168 h, with an increase in uncertainty (20% vs. 14% for the reference standard). By including a second time point, uncertainty was comparable to the reference standard (13%). Organ dosimetry can be performed using a single SPECT at 24 h or 48 h. Dosimetry based on planar scans did not provide accurate dose estimations. Accurate lesion dosimetry in [
Sections du résumé
BACKGROUND
BACKGROUND
Dosimetry in [
METHODS
METHODS
Ten patients with metastatic hormone-sensitive prostate cancer received two cycles of [
RESULTS
RESULTS
Accurate lesion dosimetry is possible using one-time point SPECT imaging at 168 h, with an increase in uncertainty (20% vs. 14% for the reference standard). By including a second time point, uncertainty was comparable to the reference standard (13%). Organ dosimetry can be performed using a single SPECT at 24 h or 48 h. Dosimetry based on planar scans did not provide accurate dose estimations.
CONCLUSION
CONCLUSIONS
Accurate lesion dosimetry in [
Identifiants
pubmed: 36692682
doi: 10.1186/s13550-023-00952-z
pii: 10.1186/s13550-023-00952-z
pmc: PMC9873880
doi:
Banques de données
ClinicalTrials.gov
['NCT03828838']
Types de publication
Journal Article
Langues
eng
Pagination
6Informations de copyright
© 2023. The Author(s).
Références
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
J Nucl Med. 2018 Jan;59(1):75-81
pubmed: 28588150
Ann ICRP. 2002;32(3-4):5-265
pubmed: 14506981
J Nucl Med. 2022 Feb;63(2):253-258
pubmed: 34088773
J Nucl Med. 2022 Apr;63(4):573-583
pubmed: 34326129
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83
pubmed: 26227531
Cancers (Basel). 2021 Aug 01;13(15):
pubmed: 34359784
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
J Nucl Med Technol. 2015 Mar;43(1):28-35
pubmed: 25655341
J Nucl Med. 2016 Aug;57(8):1170-6
pubmed: 26985056
J Nucl Med. 2020 Jul;61(7):1030-1036
pubmed: 31806772
EJNMMI Phys. 2018 Jul 5;5(1):12
pubmed: 29974391
J Nucl Med. 2016 Jul;57(7):1006-13
pubmed: 26795286
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2456-2474
pubmed: 30218316
EJNMMI Res. 2019 Aug 14;9(1):76
pubmed: 31414241
Clin Cancer Res. 2021 Jul 1;27(13):3595-3601
pubmed: 33883176
J Nucl Med. 2019 Apr;60(4):517-523
pubmed: 30291192
Oncotarget. 2016 Mar 15;7(11):12477-88
pubmed: 26871285
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
J Nucl Med. 1993 Apr;34(4):689-94
pubmed: 8455089
Eur J Nucl Med Mol Imaging. 2022 May;49(6):2064-2076
pubmed: 34932154
Clin Cancer Res. 2013 Sep 15;19(18):5182-91
pubmed: 23714732
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):460-469
pubmed: 34218300
Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1270-80
pubmed: 21318451
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1238-50
pubmed: 20411259
J Nucl Med. 2017 Mar;58(3):445-450
pubmed: 27660138
AJR Am J Roentgenol. 2007 Aug;189(2):400-8
pubmed: 17646467
Nucl Med Commun. 2017 Jan;38(1):91-98
pubmed: 27782913
Eur Urol. 2019 Jun;75(6):920-926
pubmed: 30473431
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
J Nucl Med. 2009 Mar;50(3):477-84
pubmed: 19258258
EJNMMI Phys. 2020 Jun 17;7(1):41
pubmed: 32556844